| Document |
Document Title |
|
WO/1989/004660A1 |
A method of treatment of cough and/or bronchoconstriction in mammals, including humans, which method comprises the administration to the mammal in need of such treatment, an effective amount of a 5-HT3 receptor antagonist.
|
|
WO/1988/004172A1 |
The use of azanaphthalenes of formulae (Ia), (Ib) and (Ic) for the preparation of compositions useful in the treatment of hyperproliferate skin disease: (Ia), (Ib), (Ic), wherein Ac is Ac' or Ac''.
|
|
WO/1988/003801A1 |
The use of compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT3 receptors for the relief or prevention of a withdrawal syndrome resulting from addiction to a drug or substance of abuse and/or for the suppression of d...
|
|
WO/1987/005603A1 |
A compound having formula (I), wherein R1 is the esterification residue of an alcohol (R1-OH) having from 1 to 8 carbon atoms; R2 is a substituted or unsubstituted aryl, cycloalkyl or alkyl group having from 1 to 8 carbon atoms; R3 is H ...
|
|
WO/1987/004710A1 |
New process for obtaining tropa-alcaloid raw extracts, in particular scopolamine and/or hyoscyamine from undried plant elements.
|
|
WO/1985/002847A1 |
Compounds having the formula A-CO-B-O wherein A represents groups of the formula (I), Y representing -CH2-, -NR3-, -O-, -S-, Wherein B represents -O- or -NH- and wherein D represents groups of the formula (II). Process for the production...
|
|
WO/1985/001048A1 |
Aromatic esters of amides of carboxylic acid and sulfonic acid having the formula A-B-C-D, wherein A represents groups having the formulas (I), X-Y representing -CH = CH-, -O-C-H2 or N = CH-; Z representing -CH2-, -NR3-, -O- or -S-; R1 a...
|
|
WO/1985/000170A1 |
Compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein: R1 is C1-6 alkyl; R2 is hydrogen or C1-7 acyl; R3 and R4 are independently hydrogen or C1-6 alkyl or together form C2-5 polymethylene; R5 is C4-7 alkyl, C3...
|
|
WO/1984/003281A1 |
Compounds of formula (I), or a pharmaceutically acceptable salt and/or N-oxide and/or a solvate, wherein: one of X and Y is CO and the other is NH; E is O, S or NR wherein R is hydrogen, C1-6 alkyl or a protecting group and A is C2-4 alk...
|
|
WO/1984/001151A1 |
Compounds of formula (I) and pharmaceutically acceptable salts and N-oxides and solvent aducts of any of the foregoing formula (I), wherein: G is -N= or -NR; X, Y and Z are each independently -CR1==, -N== or -NR2 or one of X, Y and Z is ...
|
|
WO/1984/000166A1 |
Di-carbocyclic or heterocyclic carbonic acid ester of a piperidinol containing an alkyl bridge, or corresponding amids or esters or amids from substituted benzoic acids or of a piperidinol or piperidylamine containing an alkyl bridge, sh...
|
|
WO/1983/000286A1 |
A method of providing a person subject to a sudden turbulent motion protection from motion sickness which comprises spraying into the nasal passages of said person a sufficient amount of scopolamine whereby said person is protected from ...
|
|
JP7492962B2 |
Provided herein are piperidine dione compounds having the following structure:wherein RN, R1, R2, R3, R4, X, L, V, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods fo...
|
|
JP7482152B2 |
The invention provides compounds of formula (I):or pharmaceutically-acceptable salts thereof, that are inhibitors of Janus kinases. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using s...
|
|
JP2024517917A |
The present invention provides general formula Ib (In the formula, R1,R2,R3,R4,R5, and Z are as described herein) The present invention relates to novel compounds having the following properties, compositions containing the compounds, an...
|
|
JP7470713B2 |
The invention provides compounds of formula (I):or pharmaceutically-acceptable salts thereof, that are inhibitors of Janus kinases and release an active metabolite in vivo. The invention also provides pharmaceutical compositions comprisi...
|
|
JP2024515545A |
Formula (I): [In the formula, R1,R2,R3,R4, Z, m, n, p and q are defined in this disclosure] or a salt thereof. Also disclosed are methods of using the compounds and pharmaceutical compositions containing the compounds to inhibit Helios p...
|
|
JP2024515204A |
The present invention relates to heteroaryl derivative compounds and uses thereof. Since the heteroaryl derivative of the present invention exhibits excellent inhibitory activity against HER2 and EGFR, it can be usefully used as a therap...
|
|
JP7458324B2 |
Provided herein is a method of preparing 4-aminoisoindoline-1,3-dione compounds with the following structure:wherein R, Ring A, and n are defined herein. Further described herein are compositions comprising an effective amount of a 4-ami...
|
|
JP2024041971A |
The present invention provides compounds and compositions for use in methods of treating disorders associated with excessive eye growth. The present invention provides azabicyclo and diazepine derivatives represented by the following for...
|
|
JP7457020B2 |
Provided are compounds that can act as a modulator of a farnesoid X receptor (FXR) and that can be useful in the treatment of diseases and/or disorders associated with the FXR Compositions including such compounds are also provided along...
|
|
JP2024038151A |
[Problem] Has MGL (monoacylglycerol lipase) regulatory properties, which can be used to treat pain, psychiatric/neurological diseases (e.g. major depressive disorder, treatment-resistant depression, anxiety depression, bipolar disorder),...
|
|
JP7450951B2 |
To provide a novel FXR agonist molecule that can be produced by a simple production process and has excellent clinical effect, and a method for producing the same.The present invention provides an FXR (farnesoid X receptor) small molecul...
|
|
JP7442828B2 |
The present invention relates to soluble epoxide hydrolase (sEH) inhibitors of formula (I)to processes for their obtention and to their therapeutic indications.
|
|
JP2024509625A |
The present disclosure provides compounds of formula (I') and pharmaceutical compositions for reducing Widely Interpaced Zinc Finger Motif (WIZ) expression levels or fetal hemoglobin (HbF) expression. and in the treatment of inherited bl...
|
|
JP2024508687A |
The present disclosure relates, in part, to chemical modulators of protein phosphatase 2A (PP2A). Compounds of the present disclosure may be used to treat cancer, diabetes, autoimmune diseases, solid organ transplant rejection, graft-ver...
|
|
JP2024506329A |
The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using them. The compounds and methods have a variety of utilities as therapeutics, diagnostics, and research tools. In particular, th...
|
|
JP2024506339A |
The present invention relates to general formula (I) (In the formula, X, Y, R1,R2,R3,R4,R5,R6,R6a(as defined herein) Provided are new bicyclic tetrahydroazepine derivatives having the following properties, compositions containing the com...
|
|
JP7217273B6 |
The invention relates to novel compounds having a TRPC6 inhibititory activity and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, using these compounds in t...
|
|
JP2024505709A |
A phenyldihydropyrimidine compound represented by formula I, a tautomer thereof, or a pharmaceutically acceptable salt thereof is provided. The phenyldihydropyrimidine compounds have excellent anti-HBV activity and are useful for produci...
|
|
JP2024505250A |
Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment and/or diagnosis. Herein, formulas (I) to (XVIII), (XXV) to (XXVII), (XXX), (XXXI), ...
|
|
JP7426939B2 |
There is provided herein a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X1, X2, Y1 to Y4, Z1 to Z3 and n have meanings provided in the description.
|
|
JP2024504252A |
The present invention relates to compounds that are agonists of muscarinic M1 and M4 receptors and are useful in the treatment of diseases mediated by muscarinic M1 and/or M4 receptors. Also provided are pharmaceutical compositions conta...
|
|
JP2024009957A |
The present invention provides an inhibitor of SHP2 and a pharmaceutical composition containing the same. For example, compounds of the following formula are shown. [Selection diagram] None
|
|
JP2024502648A |
Bridged heterocyclyl-substituted pyrimidine compounds, methods of preparation and medical uses thereof. The compounds or pharmaceutical compositions containing them can be used as JAK1 and TYK2 kinase inhibitors to treat diseases associa...
|
|
JP7416740B2 |
The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
|
|
JP2024003367A |
The present invention provides a pharmaceutical composition containing a compound having serotonin 5-HT2A receptor antagonistic and/or inverse agonistic activity or a pharmaceutically acceptable salt thereof. [Solution] Formula (I): (In ...
|
|
JP2023554392A |
The present disclosure describes chemical entities (e.g., compounds or pharmaceutically acceptable salts and/or hydrates and/or co-crystals of said compounds) that inhibit (e.g., antagonize) STING (Stimulator of Interferon Gene) and /or ...
|
|
JP2023554282A |
The present invention provides compounds that are useful in the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
|
|
JP7399869B2 |
The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.In particular, the present...
|
|
JP7398605B2 |
An FXR small molecule agonist and a preparation method therefor and a use thereof, having a structure as shown in formula (I). The compound represented by formula (I) has FXR agonistic activity and is capable of preparing drugs for treat...
|
|
JP7394893B2 |
The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.In particular, the present...
|
|
JP7386787B2 |
The present disclosure provides a compound of Formula (I'):or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, Rx, X1, n, nl, and q are as defined herein, and methods of ma...
|
|
JP2023549123A |
Disclosed herein are novel PPARγ modulators of formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the same, and methods of using the same, particularly in the treatment of cancer. [Selectio...
|
|
JP2023166614A |
To provide SHP2 phosphatase inhibitors and methods of use thereof.The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds a...
|
|
JP7383012B2 |
This invention is directed to heteroaryl-substituted sulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of di...
|
|
JP2023548368A |
The present invention relates to heterocyclic methanone compounds, particularly 3'-substituted 3-hydroxy-(8-azabicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)
-thiophene- This invention relates to a method for synthesizing a 3-yl]-methanone...
|
|
JP7373992B2 |
Disclosed are compounds useful, for example, in methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associ...
|
|
JP2023545677A |
Potent FXR small molecule agonists and methods for their preparation and uses, the structure of which is as shown in Formula I. In the formula, the definition of each substituent is as described in the specification and claims. The compo...
|
|
JP2023545171A |
Compounds of the formula: HLT and pharmaceutically acceptable salts thereof, and compositions thereof are provided that are useful for treating cancer and related conditions.
|
